Show simple item record

dc.contributor.authorSewak, S
dc.contributor.authorKosmider, S
dc.contributor.authorGanju, V
dc.contributor.authorWoollett, A
dc.contributor.authorYeow, EG
dc.contributor.authorLe, B
dc.contributor.authorHenry, M
dc.contributor.authorDebrincat, MA
dc.contributor.authorBell, R
dc.identifierpii: IMJ1987
dc.identifier.citationSewak, S., Kosmider, S., Ganju, V., Woollett, A., Yeow, E. G., Le, B., Henry, M., Debrincat, M. A. & Bell, R. (2010). Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting. INTERNAL MEDICINE JOURNAL, 40 (3), pp.201-208.
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractBACKGROUND: Androgen ablation is the standard treatment for advanced prostate cancer. However, most patients will eventually develop progressive hormone-refractory prostate cancer (HRPC). The aim of the Pacl-Vin study was to determine the efficacy and safety of paclitaxel in combination with vinorelbine in patients with HRPC, following from a phase I trial. METHODS: Thirty castrate patients with progressive, metastatic prostate cancer were enrolled. Patients were treated with paclitaxel 40 mg/m2, vinorelbine 20 mg/m2 intravenously on day 1 and day 8 of a 21-day cycle. RESULTS: Two patients demonstrated a partial response and seven patients had stable disease from a cohort of 10 patients with measurable disease. Of 30 patients assessable for prostate-specific antigen (PSA) response, 19 showed stable disease, which was maintained for at least 4 weeks, while six (20%) experienced>or=50% decline in PSA levels. Median overall survival was 7.3 months (interquartile range (IQR): 4.7-9.9 months). Median progression-free survival was 3.3 months (IQR: 2.5-7.0 months). Improvement in quality of life measures was noted after three cycles of therapy. Grade 3 and 4 toxicities were: neutropenia 8%, febrile neutropenia 4%, infection 2%, anaemia 3%, lethargy 1% and somnolescence 1%. One patient died as a result of neutropenic sepsis. CONCLUSION: In a poor prognostic cohort of patients paclitaxel and vinorelbine is a tolerable regimen, with a 20% PSA and objective response rate. The majority of patients achieved PSA stability. Furthermore, quality of life parameters, such as pain, were improved. However, the low level of activity of this regimen precludes its further testing.
dc.subjectChemotherapy; Health not elsewhere classified
dc.titlePhase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting
dc.typeJournal Article
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentMedicine - Royal Melbourne And Western Hospitals
melbourne.source.titleINTERNAL MEDICINE JOURNAL
melbourne.contributor.authorLe, Brian
melbourne.contributor.authorRogers, Margaret
melbourne.contributor.authorBELL, RICHARD
melbourne.fieldofresearch321105 Chemotherapy
melbourne.seocode209999 Other health not elsewhere classified
melbourne.accessrightsThis item is currently not available from this repository

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record